

Vol 3/Issue 4 December 2025

LIBERATE NEWSLETTER

The LIBERATE Study Receives Additional Funding

We are pleased to announce that the LIBERATE Study has received $50,000 in new funding from the University of Alberta Department of Critical Care Medicine.

As the year comes to a close we would like to thank all our amazing study sites for their efforts in continuing the LIBERATE Study's work as the highest enrolling study to investigate the role of Midodrine in managing shock in the ICU.

Frequently Asked Questions

Q. ***How do we manage patients enrolled in the study that have their vasopressors discontinued prior to receiving their first dose of study IP?***

A. The study IP should not be administered if IV vasopressors are discontinued prior to the first dose administration of study IP. The Study Coordinator should continue to follow the patient as per the study protocol (up to ICU discharge or 30 days whichever comes first and then at 90 days). A protocol deviation should be completed to indicate study IP was never administered and the reason why.

Q. ***When assessing greater than 24 hours from peak vasopressor dose as an exclusion criteria is it the 24 hour period up to the time of screening and confirmation of study eligibility or the time of randomization or first IP administration?***

A. It is 24 hours to the time of study eligibility. We urge sites to administer the study IP as close to time of eligibility as possible.





Study Coordinators Remember:

1. Enter new enrollments into the REDCap system as soon as possible to keep recruitment stats up to date.
2. Update your Screening Log and upload into your REDCap regulatory binder every month.

For more information contact:
Oleksa Rewa- Principal Investigator
rewa@ualberta.ca

Dawn Opgenorth - Project Manager
dawno@ualberta.ca

The LIBERATE Study is supported by the Canadian Critical Care Trials Program Improvement and Integration Network, the University Hospital Foundation Medical Research and Kaye Fund, the River Philip Foundation and the University of Alberta Department of Critical Care Medicine